% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Scuteri:278022,
      author       = {Scuteri, Damiana and Lawrence, Gary W and Iannacchero,
                      Rosario and Trimboli, Michele and Nicotera, Pierluigi and
                      Corasaniti, Maria T and Bagetta, Giacinto},
      title        = {{E}fficacy and safety of m{A}bs anti-{CGRP}/{CGRP} {R}
                      (eptinezumab and erenumab) or atogepant in combination with
                      onabotulinumtoxin{A} in refractory chronic migraine: a
                      clinical trial protocol.},
      journal      = {Pain management},
      volume       = {15},
      number       = {4},
      issn         = {1758-1869},
      address      = {London},
      publisher    = {Taylor $\&$ Francis},
      reportid     = {DZNE-2025-00532},
      pages        = {177 - 181},
      year         = {2025},
      abstract     = {Chronic migraine is a disabling neurovascular disorder that
                      represents the leading cause of years lived with disability
                      in people under 50 with a remarkable social burden due to
                      widespread resistance to the front-line treatments used
                      routinely in current clinical practice. The present study
                      investigates the efficacy and safety of combination therapy
                      using eptinezumab and erenumab, recently approved monoclonal
                      antibodies (mAbs) directed against calcitonin gene-related
                      peptide or its receptor, respectively, or the receptor
                      competitive antagonist atogepant together with botulinum
                      toxin type A in chronic migraine that has proven resistant
                      to front-line treatments for at least 6 weeks. To this aim a
                      retrospective and a prospective phase are designed.
                      Furthermore, a feasible salivary biomarker of migraine is
                      under investigation in the prospective stage of the study.
                      Based on recent expert opinions supporting the switch to
                      easy-to-use small molecule calcitonin gene-related peptide
                      (CGRP)-targeting, i.e. rimegepant or atogepant in
                      unresponsive patients, the present study may offer to
                      clinicians a novel treatment to enhance the therapeutic
                      preventive machinery in chronic migraine.},
      keywords     = {Migraine Disorders: drug therapy / Humans / Botulinum
                      Toxins, Type A: therapeutic use / Botulinum Toxins, Type A:
                      administration $\&$ dosage / Antibodies, Monoclonal,
                      Humanized: therapeutic use / Antibodies, Monoclonal,
                      Humanized: administration $\&$ dosage / Antibodies,
                      Monoclonal, Humanized: adverse effects / Antibodies,
                      Monoclonal, Humanized: pharmacology / Calcitonin
                      Gene-Related Peptide Receptor Antagonists: therapeutic use /
                      Calcitonin Gene-Related Peptide Receptor Antagonists:
                      administration $\&$ dosage / Drug Therapy, Combination /
                      Calcitonin Gene-Related Peptide: antagonists $\&$ inhibitors
                      / Prospective Studies / Chronic Disease / Retrospective
                      Studies / Adult / Treatment Outcome / Male / CGRP receptor
                      antagonists (Other) / anti-CGRP monoclonal antibodies
                      (Other) / anti-CGRP-R monoclonal antibodies (Other) /
                      atogepant (Other) / chronic migraine (Other) / gepants
                      (Other) / onabotulinumtoxinA (Other) / Botulinum Toxins,
                      Type A (NLM Chemicals) / erenumab (NLM Chemicals) /
                      Antibodies, Monoclonal, Humanized (NLM Chemicals) /
                      Calcitonin Gene-Related Peptide Receptor Antagonists (NLM
                      Chemicals) / eptinezumab (NLM Chemicals) / onabotulinum
                      toxin A (NLM Chemicals) / Calcitonin Gene-Related Peptide
                      (NLM Chemicals)},
      cin          = {AG Bano},
      ddc          = {610},
      cid          = {I:(DE-2719)1013003},
      pnm          = {351 - Brain Function (POF4-351)},
      pid          = {G:(DE-HGF)POF4-351},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40169386},
      doi          = {10.1080/17581869.2025.2487413},
      url          = {https://pub.dzne.de/record/278022},
}